AK....Just started a fairly large position in DRTX at $7.30 which is another antibiotic company (antibiotic was developed by Pfizer) that is IV administered only once a week for acute major bacterial skin infections and (abSSSI) skin infections. Phase III trials to be reported on any time with NDA expected before year end and approval 1H/2014. Results have been very good with minimal, if any, side effects. Idea is that the once per week IV administration will keep patients out of the hospital, or have shorter stays, and away from MRSA potential complications Much more cost effective for hospitals as well. Could you ask your spouse if she has heard of the company and what she thinks? The antibiotic is called: dalbavancin. TIA....
OT I have a position in PBYI ....have you looked at it
Re DRTX --wife will say " look for SAE's " ( serious adverse events ) --- AFFY's Omonty saved hospitals $ with few reported SAE's initially . Unfortunately major SAE's showed up at about the 20,000th patient .
As my wife reports ...Hospital mgt always looking to save $ BUT MD's are real cautious re new meds and chances of SAE's
Ot re TSRX -- Wife says its "not an OMG type improvement " -- her words . Acknowledges its an improvement but may be a slow transistion in drugs scrips ie like Lovaza to Vascepa : )
Are you in TSLA ?
AK....Wish I were in TSLA but no...never. I test drove the car early on and it's fantastic really.
Will look for sure at PBYI. In the antibiotic space...Just seems there is a drive now to get more effective and more resilient type of new antibiotics to work, and if they are something that can be given without hospital admission, or result in shorter hospital stays, then the cost savings are definitely there as well.
That is why I like TSRX.....Not an OMG antibiotic but very effective even over prolonged usage,
with apparently little side effect, and is an oral formulation. DRTX is a once a week intravenous
antibiotic for severe skin bacterial infections which cuts down hospital time as well. CEMP...not as positive on.